The antibody is a recombinant mouse antibody (clone 8d71c81e9) targeting HBEGF. The antibody can be used for studies of cancer treatment.
Figure 1 Cell proliferation following treatment with recombinant HBEGF and cross-specific antibody (8d7 1c8 1e9 i.e. “1E9”).
Different concentrations of cross-specific antibody was preincubated with ligand for an hour before addition to cells. Cell viability was assessed 48 hrs after treatment by MTT assay.
Figure 2 The results of an invasion assay on MDA-231 breast carcinoma cell line.
The invasiveness of MDA-231 cells through matrigel in the presence of 500 nM cross-specific monoclonal antibody (8d7 1c8 1e9 i.e. "1E9", 8d7 1f6 2f7 i.e. "2F7" or 8d7 1f6 2b3 i.e. "2B3" and negative control (iso-1) antibodies was assessed. The cells were left for 24 hours before being stained by Hoescht and number of invaded cells per field of view counted. Panel a is a barchart summarising the results with each antibody with Panel b showing representative images obtained using negative control antibodies and 2B3 antibodies ** indicates P<0.001. * indicates p<0.05.
Figure 3 The results of a migration assay on MDA-231 breast carcinoma cell line.
Assessed in the presence of 300 nM cross-specific monoclonal antibodies (8d7 1f6 2f7 i.e. "2F7" or 8d7 1c8 1e9 i.e. "1E9") or isotype control. The assay was left for 17 hrs before wound width was measured. The right hand panels showing representative images obtained in the absence of treatment and in the presence of 8d7 1f6 2b3 i.e. "2B3"
Figure 4 The results of an invasion assay of HUVEC cells through matrigel in the presence of 500 nM Bi-specific monoclonal antibody ((8d7 1f6 2f7 i.e. “2F7” or 8d7 1c8 1e9 i.e. “1E9” and negative control antibodies.
The cells were left for 24 hours before being stained by Hoescht and number of invaded cells per field of view counted.
Figure 5 The results of a migration assay of HUVEC cells in the presence of 500 nM cross-specific monoclonal antibody and negative control antibodies using a Boyden chamber assay.
The cells were left for 24 hours before being stained by Hoescht and number of invaded cells per field of view counted. * p<0.05, ** p<0.001 8d7 1c8 1e9 antibody, 8d7 1f6 2f7 antibody and 8d7 1f6 2b3
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-340CL | Anti-Human HBEGF Recombinant Antibody (KHK2866) | FuncS | Antibody |
TAB-015CT | Anti-Human HB-EGF Recombinant Antibody | ELISA, Inhibition, FC | Humanized antibody |
TAB-015CT-S(P) | Anti-Human HB-EGF Recombinant Antibody scFv Fragment | ELISA, Inhibition, FC | Humanized antibody |
TAB-015CT-F(E) | Anti-Human HB-EGF Recombinant Antibody Fab Fragment | ELISA, Inhibition, FC | Humanized antibody |
There are currently no Customer reviews or questions for HPAB-0094-LS. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.